BR0309558A - Derivados de quinazolina e medicamentos - Google Patents

Derivados de quinazolina e medicamentos

Info

Publication number
BR0309558A
BR0309558A BR0309558-4A BR0309558A BR0309558A BR 0309558 A BR0309558 A BR 0309558A BR 0309558 A BR0309558 A BR 0309558A BR 0309558 A BR0309558 A BR 0309558A
Authority
BR
Brazil
Prior art keywords
group
hydrogen
single bond
aliphatic hydrocarbon
present
Prior art date
Application number
BR0309558-4A
Other languages
English (en)
Inventor
Masahiko Okano
Tatsuya Oyama
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of BR0309558A publication Critical patent/BR0309558A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE QUINAZOLINA E MEDICAMENTOS". A presente invenção refere-se a um agente antiprurítico tendo um novo mecanismo de ação. A presente invenção oferece um agente antiprurítico compreendendo um composto representado pela fórmula geral (1) a seguir onde R^ 1^ representa um átomo de hidrogênio ou alquila; o anel Q representa um grupo ciclohexileno ou um grupo fenileno; A^ 1^ e A^ 2^ representam uma ligação simples ou um grupo alquileno: E representa -NHCO-; A^ 3^ representa uma ligação simples ou um grupo hidrocarboneto alifático saturado ou insaturado divalente; R^ 3^ representa um grupo hidrocarboneto alifático não-cíclico; R^ 4^ e R^ 5^ são iguais diferentes e cada um representa um átomo de hidrogênio ou alquila, ou sal farmaceuticamente aceitável do mesmo como ingrediente ativo.
BR0309558-4A 2002-04-26 2003-04-28 Derivados de quinazolina e medicamentos BR0309558A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002125452 2002-04-26
JP2002272314 2002-09-18
JP2002373400 2002-12-25
PCT/JP2003/005432 WO2003091224A1 (fr) 2002-04-26 2003-04-28 Derive et medicament de quinazoline

Publications (1)

Publication Number Publication Date
BR0309558A true BR0309558A (pt) 2005-03-01

Family

ID=29273433

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309558-4A BR0309558A (pt) 2002-04-26 2003-04-28 Derivados de quinazolina e medicamentos

Country Status (10)

Country Link
US (1) US7718663B2 (pt)
EP (1) EP1500652A4 (pt)
JP (1) JP4513566B2 (pt)
KR (1) KR20040106391A (pt)
CN (1) CN1659150A (pt)
AU (1) AU2003235956A1 (pt)
BR (1) BR0309558A (pt)
CA (1) CA2483530A1 (pt)
MX (1) MXPA04010539A (pt)
WO (1) WO2003091224A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004262533A1 (en) 2003-08-08 2005-02-17 Ulysses Pharmaceutical Products Inc. Halogenated quinazolinyl nitrofurans as antibacterial agents
CN107501099B (zh) 2004-06-24 2021-03-19 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
ES2402060T3 (es) * 2005-10-03 2013-04-26 Nippon Shinyaku Co., Ltd. Derivado de quinazolina y producto farmacéutico
JP5324785B2 (ja) * 2005-10-28 2013-10-23 武田薬品工業株式会社 複素環アミド化合物及びその用途
PL1993360T3 (pl) 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
CA2670026A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterotricyclic metalloprotease inhibitors
CN101663262B (zh) * 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
KR101955863B1 (ko) 2009-03-20 2019-03-07 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
WO2012031383A1 (zh) * 2010-09-06 2012-03-15 中国科学院广州生物医药与健康研究院 酰胺类化合物
CA2814826C (en) * 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
WO2013051159A1 (en) * 2011-10-05 2013-04-11 Nippon Shinyaku Co., Ltd. Nop receptor antagonist
IL265430B2 (en) 2012-02-27 2024-08-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
AU2015330923B2 (en) 2014-10-07 2020-03-12 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
AU2022292554A1 (en) 2021-06-14 2024-01-04 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
AU7692696A (en) 1995-12-01 1997-06-27 Novartis Ag Heteroaryl derivatives
WO1998017267A1 (en) 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
JP4713698B2 (ja) 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
US6794389B2 (en) * 2000-03-31 2004-09-21 Nippon Shinyaku Co., Ltd. Quinazoline derivatives and drugs
CA2441425A1 (en) * 2001-03-19 2002-09-26 Nippon Shinyaku Co., Ltd. Antipruritics
US20030139431A1 (en) * 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors

Also Published As

Publication number Publication date
JP4513566B2 (ja) 2010-07-28
JPWO2003091224A1 (ja) 2005-09-02
US7718663B2 (en) 2010-05-18
WO2003091224A1 (fr) 2003-11-06
AU2003235956A1 (en) 2003-11-10
KR20040106391A (ko) 2004-12-17
EP1500652A1 (en) 2005-01-26
US20050176741A1 (en) 2005-08-11
CA2483530A1 (en) 2003-11-06
CN1659150A (zh) 2005-08-24
MXPA04010539A (es) 2005-01-25
EP1500652A4 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
BR0309558A (pt) Derivados de quinazolina e medicamentos
BR9806413A (pt) Composto e uso do mesmo
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
BRPI0418074B8 (pt) derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
NO950297D0 (no) Prolinamidderivater
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
BR9804500A (pt) Derivados de amida ou sais dos mesmos.
BR0114436A (pt) Composto com anel de cinco elementos contendo nitrogênio alifático
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
BR0114253A (pt) Antagonistas de receptor de glutamato metabotrópico
BR0012697A (pt) Inibidores da diferenciação de th2
BRPI0008753B8 (pt) composto de amida, processo para preparar um composto de amida, composição farmacêutica e uso de um composto de amida
ES2124545T3 (es) Azolidindionas como agentes antihiperglucemicos.
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
CA2336412A1 (en) Medicament for treatment of diabetes
AR027296A1 (es) Derivados de 4-heteroaril-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion terapeutica
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
BR0311410A (pt) Composto de piperidina
CO4840509A1 (es) 2,4 diaminopirimidinas sustituidas, medicamento que contiene dichos compuestos para el control o la prevencion de enfermedades infecciosas y procedimiento para la preparacion de dichos compuestos"
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
ATE312815T1 (de) Neue verbindungen
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
MX9206093A (es) Derivado de oxazolidona
YU44202A (sh) Kvaternerne soli n-substituisanih cikiličnih ili ne- cikličnih amina kao farmaceutski preparati

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]